Clinical characterization of ETNK1-mutated MNs. (A) Table summarizing the clinicopathologic features of 28 patients with pathogenic mutations at the time of NGS (patients with VUS not included). (B) Kaplan-Meier survival curves of patients grouped by disease category. (C) Kaplan-Meier survival curves comparing patients with ETNK1-mutated MDS (n = 10) vs ETNK1 wild-type MDS (n = 98). (D) IPSS-M scores of patients with wild-type (n = 85) vs ETNK1-mutated MDS (n = 13; LB = 9 and EB = 4) at time of initial NGS. (E) Kaplan-Meier survival curves comparing patients that underwent HCT vs patients who did not. (F) Fishplot showing the clonal evolution of ETNK1 over serial NGS samples. ∗The targeted therapies in our cohort included venetoclax, ruxolitinib, and imatinib. AEC, absolute eosinophil count; AMC, absolute monocyte count; ANC, absolute neutrophil count; EB, excess blast; HMA, hypomethylating agent; LB, low blasts; LDH, lactate dehydrogenase; PATH, pathogenic; PB, peripheral blood; RS, ring sideroblast; WBC, white blood cell.